Keros Therapeutics (KROS) Prepaid Assets (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Prepaid Assets came in at $2.4 million in Q4 2025, down 90.86% YoY from $26.2 million in Q4 2024, and down 89.27% on a QoQ basis from $22.3 million in Q3 2025.
Keros Therapeutics (KROS) Prepaid Assets (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Prepaid Assets data on file, last reported at $2.4 million in Q4 2025.
- Quarterly Prepaid Assets fell 90.86% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (down 90.86% YoY) and the FY2025 annual result came in at $2.4 million, down 90.86% from the prior year.
- Prepaid Assets fell to $2.4 million in Q4 2025, from $22.3 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $26.8 million in Q2 2024 to a low of $210000.0 in Q4 2021.
- A 5-year average of $10.8 million and a median of $5.7 million in 2021 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets jumped 7040.16% — and 2025, when it sank 90.86%.
- Tracing KROS's Prepaid Assets over 5 years: stood at $210000.0 in 2021, then surged by 3099.52% to $6.7 million in 2022, then plunged by 85.1% to $1.0 million in 2023, then surged by 2519.38% to $26.2 million in 2024, then slumped by 90.86% to $2.4 million in 2025.
- The last three Prepaid Assets figures came in at $2.4 million (Q4 2025), $22.3 million (Q3 2025), and $26.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.03 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 22.34 Mn |
| Jun 30, 2025 | 26.78 Mn |
| Mar 31, 2025 | 21.68 Mn |
| Dec 31, 2024 | 26.22 Mn |
| Sep 30, 2024 | 20.97 Mn |
| Jun 30, 2024 | 26.85 Mn |
| Mar 31, 2024 | 20.46 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 16.54 Mn |
| Jun 30, 2023 | 376,000.00 |
| Mar 31, 2023 | 10.79 Mn |
| Dec 31, 2022 | 6.72 Mn |
| Sep 30, 2022 | 745,000.00 |
| Jun 30, 2022 | 466,000.00 |
| Mar 31, 2022 | 2.63 Mn |
| Dec 31, 2021 | 210,000.00 |
| Sep 30, 2021 | 4.73 Mn |
| Jun 30, 2021 | 4.20 Mn |